Abstract
To control the devastating group B meningococcal epidemic in New Zealand a strain-specific OMV vaccine (MeNZB) was extensively tested before vaccination of \textgreater1,000,000 people under 20 years. After the three-dose course 75\% of 6-8-month-old infants and 16-24-month-old toddlers showed four-fold increases in bactericidal antibodies. In 6-10-week-old infants a fourth dose was needed to obtain similar results. After primary vaccination, the antibody titre decline was most pronounced among the youngest but both young infants and toddlers showed a clear booster response to a fourth dose. MeNZB was safe and well tolerated. The comprehensive post-licensure safety surveillance revealed no safety concerns.
- antibodies,
- b,
- bacterial,
- child,
- humans,
- infant,
- infections,
- meningitidis,
- meningococcal
- neisseria
- new
- pharmaceutical
- preparations,
- preschool,
- safety
- serogroup
- vaccines,
- zealand,
Users
Please
log in to take part in the discussion (add own reviews or comments).